Ishak group (no. of patients) | C_{min} (ng/ml) | C_{max} (ng/ml) | C_{diff}^{b} (ng/ml) | C_{diff}^{c} (ng/ml) | AUC_{τ}^{f} (μg·h/ml) | CL/F^{d} (liters/h) |
---|---|---|---|---|---|---|

1^{e} (19) | 4,583 (3,351, 6,268) | 7,117 (5,146, 9,844) | 1,820 (1,319, 2,511) | 2,029 | 69 (48, 99) | 2.9 (2.0, 4.2) |

2 (20) | 6,021 (4,786, 7,574) | 7,087 (5,679, 8,846) | 840 (404, 1,746) | 1,060 | 74.7 (58, 95) | 2.68 (2.1, 3.4) |

3 (9) | 5,854 (4,337, 7,901) | 7,262 (5,163, 10,215) | 1,135 (590, 2,182) | 1,367 | 75.1 (53, 107) | 2.66 (1.9, 3.8) |

↵

*a*The algorithms used for*C*_{min}(*n*= 46 [all patients]),*C*_{max}(subset of*n*= 33),*C*_{diff}(subset of*n*= 31),*C*_{diff}(subset of*n*= 33), AUC_{τ}(subset of*n*= 33), and CL/*F*(subset of*n*= 33) were the observed*C*_{min}, the observed*C*_{max},*C*_{max}minus*C*_{min},*C*_{max}minus*C*_{min}, the linear trapezoidal method, and 200 mg/AUC, respectively. The subsets represent 33 additional samples drawn at 1, 2, and 4 h after dosing. The data represent the geometric means (95% confidence intervals).↵

*b*For two of the patients, the*C*_{max}and*C*_{min}were the same value. As a result, these patients had a value of zero (a nonplausible value) for the*C*_{diff}parameter on the log scale. Therefore,*n*= 31.↵

*c*The mean value for*C*_{diff}nevirapine (*n*= 33).↵

*d*CL/*F*, clearance.↵

*e*Two patients were excluded.↵

*f*Predose sample used as a surrogate for the sample obtained at 12 h.